Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516746 · ClinicalTrials.gov registry record · Phase 3
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults
A Phase 3 study of COVID-19 and SARS-CoV-2, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 32,450
- Enrollment target
- 20
- Study locations
NCT04516746: Completed Phase 3 study of COVID-19 and SARS-CoV-2, sponsored by AstraZeneca.
NCT04516746 is a Phase 3 study of COVID-19 and SARS-CoV-2 that has completed, run by AstraZeneca. The registered enrollment target is 32,450 participants, below the 38,356-participant average among 298 other COVID-19 trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04516746, a Phase 3 study of COVID-19 and SARS-CoV-2, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 32,450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
Primary Outcome
A binary response, whereby a participant with negative serostatus at baseline is defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurs ≥ 15 days post second dose of study intervention. Otherwise, a participant is not defined as a COVID-19 case. The primary efficacy analysis was performed once approximately 150 events meeting the primary efficacy outcome measure definition had occurred across the AZD1222 and placebo groups.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL AZD1222
Study Locations (20)
California
- Research Site - Berkeley
- Research Site - El Centro
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - San Diego
- Research Site - San Diego
- Research Site - San Francisco
- Research Site - San Francisco
- Research Site - Torrance
Florida
- Research Site - Coral Gables
- Research Site - Lake Worth
- Research Site - Miami Lakes
- Research Site - Orlando
Arizona
- Research Site - Phoenix
- Research Site - Scottsdale
Arkansas
- Research Site - Little Rock
Colorado
- Research Site - Denver
Connecticut
- Research Site - Danbury
Hawaii
- Research Site - Honolulu
Idaho
- Research Site - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32,450 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2023-02-10 |
| Phase | Phase 3 |
What the finished NCT04516746 record still lists
NCT04516746 is an interventional study that assigns participants to a tested intervention. Its 32,450 participants enrollment target places it among the larger protocols in the corpus, below the 38,356-participant average among 298 other COVID-19 trials with a reported enrollment target (15% lower).
The record links to 2 conditions, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04516746 names 20 study sites across 8 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04516746 about?
NCT04516746 is a clinical study titled "Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults". The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
What is the current status of trial NCT04516746?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 32,450 participants. The study started on 2020-08-28. Estimated completion is 2023-02-10.
What conditions does trial NCT04516746 study?
This clinical trial studies the following conditions: COVID-19, SARS-CoV-2.
What interventions are being tested in trial NCT04516746?
The interventions under investigation include: Placebo (BIOLOGICAL), AZD1222 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04516746?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04516746 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04516746's enrollment target sits among peer trials
32,450 11th of 298 higher than 288 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Convalescent Plasma Collection and Treatment in Pediatrics and Adults
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07282665 · 32,000 participants · Phase 3
A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
- NCT04477928 · 33,000 participants
General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery
- NCT06145724 · 33,183 participants · NA
EnCoRe MoMS: Engaging Communities to Reduce Morbidity From Maternal Sepsis (Aim 1)
- NCT03720613 · 34,532 participants
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI